N A Zakai1,2, R F Walker3, R F MacLehose3, T J Adam4, A Alonso5, P L Lutsey3. 1. Department of Medicine, Larner College of Medicine at the University of Vermont, Burlington, VT, USA. 2. Department of Pathology and Laboratory Medicine, Larner College of Medicine at the University of Vermont, Burlington, VT, USA. 3. School of Public Health, Division of Epidemiology and Community Health, University of Minnesota, Minneapolis, MN, USA. 4. Department of Pharmaceutical Care and Health Systems, College of Pharmacy, University of Minnesota, Minneapolis, MN, USA. 5. Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, USA.
Abstract
Essentials Bleeding risk by anticoagulant choice for cancer-associated venous thrombosis (CA-VTE) is unknown. 26 894 people with CA-VTE were followed for bleeding in a claims database in the United States. Hospitalized bleeding risk was similar with direct acting oral anticoagulants vs. warfarin. Relative hospitalized bleeding risk varied by cancer type and anticoagulant choice. SUMMARY: Background Direct acting oral anticoagulants (DOACs) are associated with less bleeding than traditional venous thromboembolism (VTE) treatments in the general population but are little studied in cancer-associated VTE (CA-VTE). Objective To determine whether different anticoagulation strategies for CA-VTE have different hospitalized bleeding rates. Patients/Methods We conducted a retrospective study of patients with CA-VTE, diagnosed between 2011 and 2015, in a large administrative database. Using validated algorithms, we identified 26 894 CA-VTE patients treated with anticoagulants and followed them for hospitalized severe bleeding. Cox models were used to assess bleeding risk, adjusted for age, sex, high dimensional propensity score and frailty. Results Over 27 281 person-years of follow-up (median 0.6 years), 1204 bleeding events occurred, for a bleeding rate of 4.4% per patient-year. Bleeding rates varied by cancer type, with the highest rate for upper gastrointestinal cancers (8.6%) and the lowest for breast cancer (2.9%). In Cox models (hazard ratio [HR]; 95% confidence interval [CI]), compared with warfarin, DOACS and low-molecular-weight heparin (LMWH) had similar hazards of bleeding (HR, 0.88; 95% CI, 0.69-1.11 and 0.98; 0.85-1.13). Compared with LMWH, there was no difference in hazard of bleeding with DOACs (0.86; 0.66-1.12). There was heterogeneity in bleeding risk with DOACs by cancer type, with a higher risk of bleeding in upper gastrointestinal cancers and lower risk of bleeding in prostate cancer and hematologic cancers. Conclusions In this practice-based sample of CA-VTE patients, DOACs were associated with similar bleeding risks to warfarin and LMWH. These findings suggest a complex association of bleeding risk with anticoagulant choice in cancer patients.
Essentials Bleeding risk by anticoagulant choice for cancer-associated venous thrombosis (CA-VTE) is unknown. 26 894 people with CA-VTE were followed for bleeding in a claims database in the United States. Hospitalized bleeding risk was similar with direct acting oral anticoagulants vs. warfarin. Relative hospitalized bleeding risk varied by cancer type and anticoagulant choice. SUMMARY: Background Direct acting oral anticoagulants (DOACs) are associated with less bleeding than traditional venous thromboembolism (VTE) treatments in the general population but are little studied in cancer-associated VTE (CA-VTE). Objective To determine whether different anticoagulation strategies for CA-VTE have different hospitalized bleeding rates. Patients/Methods We conducted a retrospective study of patients with CA-VTE, diagnosed between 2011 and 2015, in a large administrative database. Using validated algorithms, we identified 26 894 CA-VTEpatients treated with anticoagulants and followed them for hospitalized severe bleeding. Cox models were used to assess bleeding risk, adjusted for age, sex, high dimensional propensity score and frailty. Results Over 27 281 person-years of follow-up (median 0.6 years), 1204 bleeding events occurred, for a bleeding rate of 4.4% per patient-year. Bleeding rates varied by cancer type, with the highest rate for upper gastrointestinal cancers (8.6%) and the lowest for breast cancer (2.9%). In Cox models (hazard ratio [HR]; 95% confidence interval [CI]), compared with warfarin, DOACS and low-molecular-weight heparin (LMWH) had similar hazards of bleeding (HR, 0.88; 95% CI, 0.69-1.11 and 0.98; 0.85-1.13). Compared with LMWH, there was no difference in hazard of bleeding with DOACs (0.86; 0.66-1.12). There was heterogeneity in bleeding risk with DOACs by cancer type, with a higher risk of bleeding in upper gastrointestinal cancers and lower risk of bleeding in prostate cancer and hematologic cancers. Conclusions In this practice-based sample of CA-VTEpatients, DOACs were associated with similar bleeding risks to warfarin and LMWH. These findings suggest a complex association of bleeding risk with anticoagulant choice in cancerpatients.
Authors: Margaret C Fang; Dongjie Fan; Sue Hee Sung; Daniel M Witt; John R Schmelzer; Steven R Steinhubl; Steven H Yale; Alan S Go Journal: Med Care Date: 2017-12 Impact factor: 2.983
Authors: Alok A Khorana; Daniel Yannicelli; Keith R McCrae; Dejan Milentijevic; Concetta Crivera; Winnie W Nelson; Jeffrey R Schein Journal: Thromb Res Date: 2016-07-26 Impact factor: 3.944
Authors: T van der Hulle; P L den Exter; J Kooiman; J J M van der Hoeven; M V Huisman; F A Klok Journal: J Thromb Haemost Date: 2014-06-19 Impact factor: 5.824
Authors: Sam Schulman; Clive Kearon; Ajay K Kakkar; Patrick Mismetti; Sebastian Schellong; Henry Eriksson; David Baanstra; Janet Schnee; Samuel Z Goldhaber Journal: N Engl J Med Date: 2009-12-10 Impact factor: 91.245
Authors: Martin H Prins; Anthonie W A Lensing; Tim A Brighton; Roger M Lyons; Jeffrey Rehm; Mila Trajanovic; Bruce L Davidson; Jan Beyer-Westendorf; Ákos F Pap; Scott D Berkowitz; Alexander T Cohen; Michael J Kovacs; Philip S Wells; Paolo Prandoni Journal: Lancet Haematol Date: 2014-09-28 Impact factor: 18.959
Authors: Ximena Jordan Bruno; Insu Koh; Pamela L Lutsey; Robert F Walker; Nicholas S Roetker; Katherine Wilkinson; Nicolas L Smith; Timothy B Plante; Allen B Repp; Chris E Holmes; Mary Cushman; Neil A Zakai Journal: J Thromb Haemost Date: 2022-04-27 Impact factor: 16.036
Authors: Pamela L Lutsey; Rob F Walker; Richard F MacLehose; Faye L Norby; Line H Evensen; Alvaro Alonso; Neil A Zakai Journal: J Am Heart Assoc Date: 2021-10-08 Impact factor: 5.501
Authors: Pamela L Lutsey; Richard F MacLehose; J'Neka S Claxton; Rob F Walker; Terrence J Adam; Alvaro Alonso; Neil A Zakai Journal: Vasc Med Date: 2020-07-27 Impact factor: 3.239